孕期使用那他珠单抗治疗多发性硬化症——持续争论的临床和生物伦理学方面。
Natalizumab treatment during pregnancy in multiple sclerosis-clinical and bioethical aspects of an ongoing debate.
机构信息
Departmentof Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Department of Christian Philosophy, University of Innsbruck, Innsbruck, Austria.
出版信息
Wien Med Wochenschr. 2022 Nov;172(15-16):373-378. doi: 10.1007/s10354-022-00913-6. Epub 2022 Feb 10.
BACKGROUND
Natalizumab is an approved treatment for relapsing remitting multiple sclerosis; however, its safety during pregnancy is not formally proven.
CASE PRESENTATION
We report a woman with multiple sclerosis being treated with natalizumab before pregnancy. After withdrawal of natalizumab, she suffered a severe, disabling rebound. In agreement with the patient, natalizumab was restarted during pregnancy. Our patient improved substantially and gave birth to a healthy boy.
CONCLUSION
Use of natalizumab during pregnancy may be an option in highly active multiple sclerosis.
背景
那他珠单抗是一种已被批准用于治疗复发缓解型多发性硬化症的药物，但它在怀孕期间的安全性尚未得到正式证实。
病例介绍
我们报告了一例在妊娠前接受那他珠单抗治疗的多发性硬化症患者。在停用那他珠单抗后，她出现了严重的、致残性的反弹。经与患者协商，那他珠单抗在怀孕期间被重新使用。我们的患者病情显著改善，并生下了一个健康的男孩。
结论
在高度活跃的多发性硬化症中，怀孕期间使用那他珠单抗可能是一种选择。
Zotero 插件